Glutathione: Skin Trials, Antioxidant Markers and Injection Safety

by

Direct answer

Glutathione’s cosmetic and antioxidant findings are mixed. One short oral trial found pigmentation differences at two of six sites; another found no significant full-sample pigmentation benefit and a limited wrinkle signal at one site. A six-month trial raised some glutathione markers, while a four-week trial did not. Small sublingual and micellar comparisons tested particular products and biomarkers, rather than lasting whitening, detoxification or longevity. The trials have disclosed commercial product support or author ties, with some financial terms unknown. U.S. FDA alerts address unsuitable dietary-grade ingredients and endotoxin-contaminated injections; the Philippine warning distinguishes cosmetic injection from a medical cisplatin indication. These reports do not prove every oral product safe or every medical injection contraindicated.

Key takeaways
  • Glutathione is a tripeptide made by the body and marketed for skin lightening and antioxidant benefits. (Richie 2015 trial; 2025 narrative review)
  • A commercially supported trial gave 500 mg/day for 4 weeks to 60 Thai medical students. Between-group melanin-index differences were significant at 2 of 6 sites. A separate 12-week manufacturer-funded trial did not find a significant pigmentation effect across the full sample. Neither establishes uniform, lasting whitening (Arjinpathana 2012; Weschawalit 2017).
  • A six-month manufacturer-funded trial reported increased glutathione in several compartments among 54 completers. A tiny high-dose immune-assay subset improved from its own baseline; that is not a proven between-group clinical immune benefit. Another four-week trial found no significant glutathione or oxidative-marker benefit over placebo (Richie 2015; Allen/Bradley 2011).
  • Cosmetic IV glutathione has unestablished benefit and important safety concerns. U.S. FDA alerts concern inappropriate dietary-grade ingredients and endotoxin contamination in compounded injections. The Philippine FDA warns against injectable skin-lightening use while distinguishing an approved medical chemotherapy indication. (U.S. FDA 2019 alert; U.S. FDA 2026 alert; Philippine FDA advisory)
  • The trials assessed pigmentation, selected skin parameters or biochemical markers. They do not demonstrate clinically meaningful toxin clearance, longer life or general rejuvenation. Weschawalit reported a limited wrinkle signal at one skin site; that differs from proof of general anti-aging (Richie; Allen/Bradley; Weschawalit).
  • Evidence boundary: the small commercially supported trials have mixed, preparation-specific findings. Biomarker or selected skin-parameter changes are not clinical detoxification, disease-prevention or longevity benefits. Cosmetic injection adds documented product-quality and regulatory concerns; the cited alerts are not head-to-head safety comparisons (skin trial; skin-parameter trial; oxidative-marker trial; U.S. FDA; Philippine FDA).

Table of contents

Claim Evidence Source Funding/conflict Evidence boundary
Oral skin lightening 60 students, 500 mg/day, 4 weeks; significant between-group melanin contrast at 2 of 6 sites Arjinpathana 2012; publisher JSP partial support/capsules; no COI and no sponsor research/manuscript role declared Small selected population; no durable or uniform effect established
Skin lightening and wrinkle measures 60 women, 250 mg/day reduced or oxidized glutathione versus placebo, 12 weeks; full-sample pigmentation null, selected wrinkle signal Weschawalit 2017 Kyowa Hakko funding and supplied products; no COI declared Exploratory sites/subgroups; not general rejuvenation or lasting whitening
Glutathione stores and oxidative markers Six-month compartment changes in 54 completers; separate four-week trial showed no significant benefit over placebo Richie; full paper; Allen/Bradley Richie: Kyowa Hakko product/support and author ties. Allen/Bradley: Kohjin product/funding plus author NIH support Mixed biomarker findings; no demonstrated disease-prevention benefit
General clinical detoxification The cited marker trials did not measure clearance of a named toxin or a clinical detoxification outcome Richie; Allen/Bradley Both commercially supported; author/public support declared separately A biomarker change cannot establish toxin clearance
General anti-aging or longer life One skin-parameter trial reported a wrinkle signal at a selected site, without a lifespan or general rejuvenation outcome Weschawalit 2017 Kyowa Hakko funding/products Skin measurements are distinct from whole-body aging or longevity
Cosmetic IV as a safe/effective upgrade U.S. alerts address unsuitable dietary-grade material/endotoxin; Philippine advisory warns against cosmetic injection and distinguishes medical use U.S. FDA 2019; U.S. FDA 2026; Philippine FDA 2019 Official regulatory safety communications Not an efficacy trial or quantified oral-versus-IV risk comparison

What glutathione is

Glutathione consists of glutamate, cysteine and glycine and participates in intracellular antioxidant processes. The body makes and recycles its reduced and oxidized forms. It is marketed for skin lightening, detoxification and anti-aging, but these distinct outcomes require their own human evidence. Oral biomarker changes in a small commercially funded trial do not establish broad clinical benefits (Richie 2015).

Preparations and delivery routes

Reduced and oxidized glutathione, standard capsules, delivery-enhanced oral products and sublingual preparations are different interventions. A shared ingredient name does not establish matched exposure, clinical benefit or safety.

Preparation Description Human study context Evidence boundary
Standard oral capsules Reduced glutathione; brands and doses differ Arjinpathana 500 mg/day 4 weeks; Richie 250/1000 mg/day 6 months; Allen/Bradley 1000 mg/day 4 weeks (skin trial; stores trial; null marker trial) Mixed skin/biomarker outcomes; small selected samples do not establish all-product or long-term safety
Liposomal and micellar oral preparations Distinct delivery systems, not interchangeable labels A 14-person 2026 crossover compared specific liposomal 300 mg, LipoMicel 300 mg and standard 500 mg products. LipoMicel increased short-term whole-blood exposure versus standard (original PK trial) Unequal doses, commercial author/product ties and limited participant blinding; not a skin-benefit or long-term safety comparison
Sublingual preparation A particular tablet intended to dissolve under the tongue A 20-person crossover used Sublinthion 450 mg/day, oral glutathione 450 mg/day and NAC 200 mg/day for 21 days each; no placebo. A GSH/GSSG change favoured sublingual over oral (Schmitt 2015) Le Stum sponsor/product and employee ties; not proof of all-sublingual cosmetic benefit or safer use
N-acetylcysteine (NAC) A cysteine-donor precursor, distinct from glutathione NAC 200 mg/day was a comparator in the small Schmitt biomarker crossover (original trial) The study does not establish NAC skin whitening, a generally safer alternative or an optimal clinical dose
Intravenous glutathione Injected preparation; cosmetic and medical indications differ U.S. FDA alerts concern compounding material/endotoxin. Philippine FDA warns against cosmetic skin-lightening use, while describing a cisplatin adjunct indication (2019 FDA; 2026 FDA; Philippine advisory) No cosmetic upgrade recommendation or universal medical contraindication follows from these alerts
Label-reading: check the exact preparation, amount and route. The small sublingual and micellar studies tested particular products and biochemical outcomes; they do not establish that every product with the same delivery label has the same effect (sublingual trial; micellar trial). Dietary-supplement-grade raw material is not suitable merely because a compounder tests it for contamination (FDA warning).

How it works

The pigmentation trials measured skin parameters rather than isolating a tyrosinase mechanism in people. Richie’s trial did not determine what fraction of an oral dose entered the body intact. Its tiny NK subset had a within-arm baseline change, not a demonstrated clinical immune benefit. Blood concentrations and proposed biochemical pathways are distinct from toxin clearance, disease prevention and longevity (Arjinpathana; Weschawalit; Richie full paper).

Claims and evidence

Skin lightening, body glutathione concentrations, toxin clearance and aging are separate questions. The 2025 narrative review discusses these claims, but does not provide a reliable substitute for checking the original outcomes (narrative review).

  • Skin lightening: A commercially supported trial in 60 Thai medical students used 500 mg/day for 4 weeks. Between-group melanin-index differences were significant at 2 of 6 sites. This limited trial does not establish dramatic, uniform or lasting benefit (Arjinpathana & Asawanonda 2012).
  • Narrative review limits: the 2025 review calls for larger and longer studies and reports no author financial support or relevant relationships. It also misdescribes Allen/Bradley as a melanin study; the original measured oxidative markers and glutathione status. Review-author declarations do not clear underlying trial finances (review; Allen/Bradley original).
  • Internal markers: Richie reported compartment changes after six months, whereas Allen/Bradley found no significant between-group marker changes after four weeks. Different products, durations and samples limit direct interpretation; neither establishes general clinical benefit (Richie; Allen/Bradley).
  • “Detox” and aging: the cited marker trials did not test clinical toxin clearance or lifespan. Weschawalit did test wrinkles, with a signal at a selected site but no significant full-sample pigmentation or elasticity effect. That does not establish general rejuvenation (Richie; Allen/Bradley; Weschawalit).
  • Cosmetic injection: the Philippine FDA’s 2019 advisory warns against skin-lightening injection and distinguishes an approved adjunctive cisplatin indication. U.S. FDA warnings in 2019 and 2026 address unsuitable raw material and endotoxin-related compounding incidents. These reports do not quantify every IV product’s risk or compare it directly with oral treatment (Philippine advisory; FDA 2019; FDA 2026).

Benefits by claim

Skin whitening/brightening

Arjinpathana randomized 60 Thai medical students to 500 mg/day or placebo for 4 weeks. Significant between-group melanin contrasts occurred at 2 of 6 sites; one treated participant reported flatulence. JSP partly supported the trial and supplied capsules; authors declared no COI or sponsor research/manuscript role (original skin trial). Weschawalit randomized 60 women to 250 mg/day reduced glutathione, oxidized glutathione or placebo for 12 weeks; 57 completed. Full-sample pigmentation differences were not significant, although a small older subgroup showed a site-specific signal. Kyowa Hakko funded/provided products. The findings do not establish uniform or lasting whitening (original 12-week trial).

"Master antioxidant" / raising body glutathione stores

Richie treated 60 adults and analyzed 54 six-month completers receiving 250 or 1000 mg/day or placebo. Several blood and cheek-cell glutathione measures increased, but this does not establish disease prevention or detoxification. The NK assay included only 6 high-dose and 6 placebo participants; the reported high-dose change was significant against its own baseline. Kyowa Hakko supplied/funded treatment and Richie disclosed research/travel support. The sponsor’s declared no-role statement covers trial conduct, data and writing, without addressing design (complete original). Allen/Bradley found no significant between-group glutathione or oxidative-marker change after 1000 mg/day for 4 weeks in 39 completers; Kohjin funded/provided the product, with separate NIH author support (original null trial).

"Detox"

The cited trials measured glutathione compartments, redox ratios or urinary oxidation markers, rather than clearance of a named toxin or a clinical detoxification outcome. A real biochemical antioxidant role and a marker response do not establish a “detox” supplement benefit (Richie outcomes; Allen/Bradley outcomes).

Anti-aging

Weschawalit did measure skin-aging parameters. A reduced-glutathione group showed a wrinkle difference at one sun-protected arm site, among multiple site/subgroup comparisons; full-sample pigmentation, elasticity and subjective ratings did not show significant benefit. This short manufacturer-funded trial does not establish whole-body rejuvenation, longer life or a durable cosmetic result (original Results/limitations).

NAC as a precursor alternative

NAC supplies a cysteine precursor for glutathione synthesis, but is a distinct intervention. In Schmitt’s 20-person crossover, NAC 200 mg/day was compared with two glutathione 450 mg/day products over 21-day periods, without placebo. The change in GSH/GSSG did not differ significantly between NAC and sublingual glutathione. This small sponsor-linked marker study does not establish NAC whitening, general clinical superiority or a safer alternative (original Methods/Results).

Claims and limits

Claim Verdict Evidence basis
Short-term pigmentation change Limited site-specific signal in one trial; full-sample result null in another Arjinpathana; Weschawalit
Uniform, durable whitening Not established by the short selected-population trials 4-week trial; 12-week trial
Raised glutathione/antioxidant markers Some products and durations showed changes, others did not; not a clinical health outcome Richie; Allen/Bradley
Clinical detoxification The assessed marker trials did not test named-toxin clearance Richie; Allen/Bradley
General anti-aging Limited wrinkle measure is not general rejuvenation or lifespan benefit Weschawalit
Cosmetic IV upgrade Specific regulatory warnings; no head-to-head safety/efficacy endorsement FDA 2019; FDA 2026; Philippine FDA

Safety findings and gaps

Reported concern Route/context Evidence boundary Source
Reported events in oral trials Studied capsules Minor symptoms reported; Weschawalit also had two transient liver-enzyme withdrawals, with their arms and causal attribution unspecified Arjinpathana; Richie; Weschawalit; Allen/Bradley
Long-term and rare harms Oral/sublingual products studied Small selected samples and short formulation comparisons cannot settle long-term, pregnancy or rare-harm safety. The featured capsule trials do not establish zinc depletion Richie; Weschawalit; Schmitt; Solnier
Acute endotoxin-consistent infusion reactions Compounded intravenous products 2019 affected Letco material; 2026 involved Medisca lot 229536 with at least 30 reported reactions. Investigations do not provide a universal all-product incidence FDA 2019; FDA 2026
Stevens–Johnson syndrome and other serious concerns Cosmetic injectable use Listed in the 2019 Philippine warning; this advisory does not quantify incidence Philippine FDA 2019-182
Liver/kidney/nervous-system toxicity concerns Cosmetic injectable use Listed by Philippine FDA; vitamin C-combination stone/G6PD concerns are separate from effects of glutathione alone Philippine advisory
Dietary-grade raw material/endotoxin Compounded injections FDA warns against using dietary-supplement-grade glutathione for sterile injectables; testing does not by itself make the material suitable 2019 FDA; 2026 FDA
Cosmetic injection dosing uncertainty Skin-lightening use Philippine FDA’s 2019 advisory stated that an approved cosmetic regimen was not established; this is historical, jurisdiction-specific guidance 2019 advisory
Safety-critical: U.S. FDA alerts in 2019 and 2026 concern dietary-grade material and endotoxin-contaminated compounded injections; the 2026 investigation involved at least 30 reported reactions linked to a Medisca lot (FDA 2019; FDA 2026). The Philippine FDA’s 2019 advisory warns against cosmetic skin-lightening injections while distinguishing an approved adjunctive cisplatin indication (original advisory). These are regulator communications, not head-to-head trials proving every oral product safer or every medical injection contraindicated. Do not self-administer cosmetic injections.

Medicines and interaction limits

Context What these sources establish Practical boundary Source
Cancer treatment NCI PDQ discusses general antioxidant/supplement interactions; it does not quantify each glutathione–treatment combination Discuss the exact product and treatment with the oncology team NCI patient PDQ
Multiple supplement ingredients The small trial protocols do not establish every combination’s safety; Philippine FDA discusses separate vitamin C-related concerns in injections Check each active ingredient and route; do not infer compatibility from antioxidant labels crossover protocol; PK eligibility; Philippine warning
Regular medicines, including glucose/BP/thyroid/psychiatric or clotting treatments These selected trials excluded various medicines or illnesses and were not designed to quantify the listed combinations A missing interaction estimate is not proof of compatibility; obtain regimen-specific prescribing advice Richie eligibility; Allen/Bradley eligibility; Schmitt eligibility; Solnier eligibility
Interaction limits: the oral and formulation studies described here do not quantify safety for every drug combination. Selected eligibility criteria restrict extrapolation to people with illnesses or regular medicines (Richie; Allen/Bradley; Schmitt; Solnier). During cancer treatment, discuss supplements with the oncology team; general antioxidant advice is not a universal glutathione interaction rule (NCI PDQ).

Who should seek advice first

  • Avoid self-directed cosmetic injection. The Philippine FDA 2019 skin-lightening warning and U.S. FDA 2019/2026 compounding alerts have specific scopes; medical indications require individualized care (Philippine advisory; FDA 2019; FDA 2026).
  • People receiving cancer treatment should discuss glutathione and other supplements with their oncology team; interactions and decisions depend on the treatment (NCI).
  • The trials reviewed do not establish pregnancy or breastfeeding safety. Solnier excluded pregnancy, and pregnancy appeared among Arjinpathana’s discontinuation conditions. These protocols are not evidence of safety in those populations (skin-trial protocol; PK eligibility).
  • For dramatic, uniform or permanent whitening, the evidence is inadequate: Arjinpathana found significant contrasts at 2 of 6 sites in a short trial, while Weschawalit’s full-sample pigmentation result was null (4-week trial; 12-week trial).
  • High-dose or long-term use is not established as safe by the selected small trials. The cited capsule papers do not show a zinc-depletion signal or justify routine zinc supplementation solely because glutathione is used; they are not an all-safety-literature review (Arjinpathana; Richie; Allen/Bradley).

Studied doses and timing

Protocol/context Studied amount or limit Source
Skin study protocols Arjinpathana 250 mg twice daily before meals for 4 weeks; Weschawalit 250 mg once at bedtime for 12 weeks. These are study instructions, not optimal timing advice Arjinpathana Methods; Weschawalit Methods
Stores/oxidative-marker protocols Richie 250 or 1000 mg/day 6 months; Allen/Bradley 500 mg twice daily 15 minutes before meals 4 weeks. Outcomes differed; dose superiority is not a clinical-benefit conclusion Richie; Allen/Bradley
Cosmetic IV regimen Philippine FDA’s 2019 advisory did not establish an approved skin-lightening regimen; its cisplatin adjunct indication is a distinct medical context original advisory
Form-comparison protocols Schmitt 450 mg/day oral/sublingual versus NAC 200 mg/day 21-day periods; Solnier 300/300/500 mg single-dose crossover and uncontrolled 600 mg/day micellar extension Specific biochemical comparisons, not a generally recommended route or cosmetic regimen (Schmitt; Solnier)
Route matters: injection introduces material-quality, sterility and administration concerns addressed by regulators. That distinction does not itself quantify how much safer a specific oral, sublingual or liposomal product is. The small non-injection studies do not establish lasting whitening or a long-term all-product safety guarantee (FDA 2019; FDA 2026; Philippine FDA; skin trial; sublingual trial; PK trial).

Limits of mechanistic evidence

Clinical conclusions here concern the actual human study endpoints and official warnings. The oral skin and marker trials and the small formulation comparisons have commercial product support or author relationships; they are not independent endorsements. Cell/animal hypotheses do not fill clinical gaps. The 2025 narrative review contains specific outcome/citation problems and is treated as secondary context (skin trial; stores trial; skin parameters; null markers; sublingual; micellar; narrative review).

Funding, conflicts and source roles

Follow the money

Research funding at a glance

Funding & backersSource & studyClaim & limits

7 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.

No single explicit tier could be mapped. This graphic does not assign a new tier or infer independence.

Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.

Source Disclosed support/relationships What remains unknown
Arjinpathana 2012 JSP partial support and supplied capsules; no COI and no sponsor design/conduct/analysis/manuscript role declared Amounts, supply payment terms and ultimate backers not itemised (trial; publisher)
Richie 2015 / Allen–Bradley 2011 Richie: Kyowa Hakko funding/products, author research/travel support, university immune-assay support; sponsor no-role declaration does not cover design. Allen/Bradley: Kohjin trial funding/product, Natural Factors encapsulation, separate NIH author support No complete cash/contracts/ultimate funding chain; declared no-role/no-COI statements do not erase support (Richie original; Allen/Bradley original)
Alzahrani 2025 narrative Review authors declare no financial support or relevant financial relationships Declarations concern review authors, not every constituent trial; concrete source/outcome misdescriptions limit its clinical role (review; misdescribed original)
U.S. FDA 2019/2026 Official federal drug-regulator compounding safety communications Incident-specific material/quality warnings; no formal paper-finance or all-product safety certificate (2019 alert; 2026 alert)
Philippine FDA 2019-182 Official national medicines-regulator advisory Safety warning with a distinct medical-indication context, not an efficacy trial or all-product risk estimate (original advisory)
NCI patient PDQ Official NCI informational summary/editorial process General antioxidant caution, not glutathione-specific trial or formal NCI treatment policy; each author/constituent financial chain not traced (PDQ)
Additional skin/form trials Weschawalit: Kyowa Hakko funding/products. Schmitt: Le Stum sponsor/product, Denis/Vicenzi employees. Solnier: ISURA OA fund/employees/advisory role, Factors Group/InovoBiologic products, company owner/consultant and patent interests No complete financial amounts, supply terms or ultimate backing. Nonprofit/no-external-funding/no-COI descriptions are not independence certificates (Weschawalit; Schmitt; Solnier)

Frequently asked questions

Does oral glutathione actually whiten or brighten skin?

Findings are mixed. Arjinpathana found significant between-group melanin differences at 2 of 6 sites after 500 mg/day 4 weeks in 60 Thai students. Weschawalit did not find significant full-sample pigmentation benefit with 250 mg/day reduced or oxidized glutathione over 12 weeks in 60 women. Neither supports dramatic, uniform or lasting whitening (Arjinpathana; Weschawalit).

Is IV glutathione safe?

Cosmetic injection is not an established safe upgrade. The Philippine FDA warns against injectable skin-lightening use and distinguishes a medical chemotherapy indication. U.S. FDA alerts concern unsuitable dietary-grade raw material and contaminated compounded injections. These warnings have specific scopes and do not establish a universal contraindication to every medical use. (Philippine FDA advisory; U.S. FDA 2019 alert; U.S. FDA 2026 alert)

Does glutathione "detox" the body?

The trials described measured biochemical markers rather than clearance of a named toxin or a clinical detoxification outcome. The marker findings are mixed and do not establish that taking glutathione “detoxes” a person (Richie; Allen/Bradley).

Can the body actually absorb oral glutathione, or is it broken down in the gut?

Richie’s tested product raised some glutathione measures over six months, while Allen/Bradley’s four-week study found no significant benefit over placebo. Small sublingual/micellar comparisons also measured circulating markers. These designs do not determine the fraction absorbed intact or prove skin, detoxification or longevity benefit (Richie; Allen/Bradley; Schmitt; Solnier).

Does popularity establish benefit or safety?

No. This article’s clinical sources do not establish current hashtag rankings or which countries lead engagement. The Philippine FDA 2019 advisory addresses cosmetic injection safety rather than popularity or oral efficacy; clinical decisions require evidence about the actual preparation and outcome (original advisory).

Is NAC a proven cosmetic or safer substitute?

NAC is a distinct precursor intervention. The small Schmitt trial compared 200 mg/day NAC with 450 mg/day oral or sublingual glutathione over 21-day periods, without placebo; it tested markers rather than skin whitening or long-term comparative safety. It does not establish NAC as a cosmetic substitute or a generally safer product (original crossover).

Sources and funding notes

  • Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. Journal of Dermatological Treatment. 2012;23:97–102. Partly JSP Pharmaceuticals-supported. (Arjinpathana 2012 trial; publisher funding disclosure)
  • Richie JP Jr, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. 2015; NCT01044277. Kyowa Hakko support/products and author research/travel ties; sponsor no-role declaration does not address design (record; original). Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers. Journal of Alternative and Complementary Medicine. 2011. Kohjin trial funding/product and NIH author support; no competing financial interests declared (original).
  • Alzahrani TF, et al. Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review. Cureus. 2025. Review authors declare no financial support/relevant relationships; this is secondary context with source/outcome errors, including its description of Allen/Bradley as a melanin study (review; original marker trial).
  • U.S. FDA 2019 and 2026 glutathione sterile-compounding alerts. Official incident-specific material/endotoxin warnings (June 2019; August 2026).
  • Philippine FDA. Advisory No. 2019-182: Unsafe Use of Glutathione as Skin Lightening Agent. 5 July 2019. Regulator warning; distinguishes cosmetic use from approved medical adjunct use. (Philippine FDA advisory)
  • NCI. Cancer Therapy Interactions With Foods and Dietary Supplements (PDQ), patient version. General antioxidant/supplement information, not a glutathione-specific interaction trial or formal NCI treatment policy (official summary).
  • Weschawalit S, et al. Glutathione and its antiaging and antimelanogenic effects. Clinical, Cosmetic and Investigational Dermatology. 2017. Kyowa Hakko funded/provided products; no COI declared. Full-sample pigmentation was null, selected wrinkle/subgroup findings exploratory; two liver-enzyme withdrawals were not allocated by arm in Results (original trial).
  • Schmitt B, et al. Effects of N-acetylcysteine, oral glutathione and a novel sublingual form on oxidative stress markers. Redox Biology. 2015. Le Stum sponsored/provided products; company employees coauthored (original). Solnier J, et al. A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans. Antioxidants. 2026. Short product-specific PK pilot with ISURA/company/patent relationships, not a clinical-benefit or long-term safety trial (original).

Have a question — or want us to cover something?

Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.

We store your topic, message, optional email, and this page so we can manage and reply to the request. Do not include diagnoses, medications, or other sensitive medical information. See our Privacy Policy.